<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2022-16-1-143-148</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-6696</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Особенности наружной терапии аллергических заболеваний кожи у детей</article-title><trans-title-group xml:lang="en"><trans-title>Features of external therapy of allergic skin diseases in children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0090-6980</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Холодова</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kholodova</surname><given-names>I. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., профессор кафедры педиатрии имени Г.Н. Сперанского </p><p>125993, Россия, Москва, ул. Баррикадная, д. 2/1, стр. 1</p></bio><bio xml:lang="en"><p> Dr. Sci. (Med.), Professor of the Department of Pediatrics named after G.N. Speransky</p><p> 2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993, Russia; </p></bio><email xlink:type="simple">chin5@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российская медицинская академия непрерывного профессионального образования</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>01</day><month>03</month><year>2022</year></pub-date><volume>0</volume><issue>1</issue><fpage>143</fpage><lpage>148</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Холодова И.Н., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Холодова И.Н.</copyright-holder><copyright-holder xml:lang="en">Kholodova I.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/6696">https://www.med-sovet.pro/jour/article/view/6696</self-uri><abstract><p>Доказано, что развитие воспалительного процесса в коже связано прежде всего с дефектами иммунной системы, в частности с Т-лимфоцитами. В острой фазе заболевания преобладает Th2-ответ, когда происходит стимуляция Th2-клеток с последующей гиперпродукцией IgE, в хронической – происходит переключение с Th2- на Th1-иммунный ответ, при этом в процесс подключается значительное количество провоспалительных цитокинов ИЛ-4, ИЛ-5, ИЛ-13, ИЛ-31 и ИФН-γ. Кроме того, известно, что кожные реакции могут вызывать не только пищевые аллергены, но и аллергены к клещам домашней пыли, энтеротоксинам золотистого стафилококка, плесневым грибам. Распространенность атопического дерматита среди детского населения составляет до 20%, при этом у половины детей поражение кожи характеризуется тяжелым длительным течением, что нарушает качество их жизни. Основной целью наружной терапии дерматозов является достижение контроля над субъективными симптомами (особенно зуд кожи), а также регресс воспалительных проявлений с последующей стойкой ремиссией аллергического процесса. Местная терапия проявлений атопического дерматита основана на адекватном применении различных наружных форм, а также средств в соответствии с воспалительными проявлениями и локализацией воспалительного процесса. В статье описаны клинические случаи лечения атопического дерматита с различными вариантами его течения с использованием крема метилпреднизолона ацепоната с керамидами, эмолентных средств. Показано, что сочетанное применение топических кортикостероидов и эмолентов способствует быстрому уменьшению воспаления, сухости кожи и зуда. Подчеркнуто отсутствие токсических и побочных эффектов на данный вид терапии у детей при высокой эффективности лечения.</p></abstract><trans-abstract xml:lang="en"><p>The development of inflammatory process in the skin has proven to be primarily associated with the immune system defects, in particular T-lymphocytes: the Th2 response predominates during the acute phase of the disease, when Th2 cells are stimulated with the subsequent hyperproduction of IgE; during the chronic phase, the Th2- shifts to Th1-immune response. At the same time, a significant amount of pro-inflammatory cytokines IL-4, IL-5, IL-13, IL-31 and IFN-γ move into this process. In addition, it is known that skin reactions can be induced not only by food allergens, but also by other allergens (house dust mites, Staphylococcus aureus enterotoxins, mold fungi). The prevalence of atopic dermatitis among the children’s population is up to 20%, while half of the children have skin lesions characterized by a severe long-term course, which violates their quality of life. The main goal of external therapy of dermatoses is to achieve control over subjective symptoms (especially skin itching), as well as regression of inflammatory manifestations with subsequent persistent remission of the allergic process. Local therapy of manifestations of atopic dermatitis is based on the adequate use of various external forms, as well as means in accordance with the inflammatory manifestations and localization of the inflammatory process. The article describes clinical cases of treatment of atopic dermatitis with various variants of its course using methylprednisolone aceponate cream with ceramides, emollient agents. It has been shown that the combined use of topical corticosteroids and emollients contributes to a rapid reduction of inflammation, dry skin and itching. The absence of toxic and side effects on this type of therapy in children with high treatment efficiency is emphasized.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>наружная терапия</kwd><kwd>метилпреднизолона ацепонат</kwd><kwd>керамиды</kwd><kwd>эмоленты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>children</kwd><kwd>external therapy</kwd><kwd>methylprednisolone aceponate</kwd><kwd>ceramides emollients</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Кубанов А.А., Намазова-Баранова Л.С., Хаитов Р.М., Ильина Н.И., Амбарчян Э.Т., Аршинский М.И. и др. Атопический дерматит: клинические рекомендации. М.; 2020. 69 с. Режим доступа: https://www.nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf.</mixed-citation><mixed-citation xml:lang="en">Kubanov A.A., Namazova-Baranova L.S., Khaitov R.M., Ilʹina N.I., Ambarchyan Eh.T., Arshinskiy M.I. et al. Atopic dermatitis: clinical recommendations. Moscow; 2020. 69 p. (In Russ.) Available at: https://www.nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–446. https://doi.org/10.1038/ng1767.</mixed-citation><mixed-citation xml:lang="en">Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–446. https://doi.org/10.1038/ng1767.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">McGirt L.Y., Beck L.A. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):202–208. https://doi.org/10.1016/j.jaci.2006.04.033.</mixed-citation><mixed-citation xml:lang="en">McGirt L.Y., Beck L.A. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):202–208. https://doi.org/10.1016/j.jaci.2006.04.033.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAK-STAT. 2013;2(3):e24137. https://doi.org/10.4161/jkst.24137.</mixed-citation><mixed-citation xml:lang="en">Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAK¬STAT. 2013;2(3):e24137. https://doi.org/10.4161/jkst.24137.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Werfel T., Allam J.P., Biedermann T., Eyerich K., Gilles S., Guttman-Yassky E. et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. https://doi.org/10.1016/j.jaci.2016.06.010.</mixed-citation><mixed-citation xml:lang="en">Werfel T., Allam J.P., Biedermann T., Eyerich K., Gilles S., Guttman-Yassky E. et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. https://doi.org/10.1016/j.jaci.2016.06.010.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hill D.A., Spergel J.M. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137. https://doi.org/10.1016/j.anai.2017.10.037.</mixed-citation><mixed-citation xml:lang="en">Hill D.A., Spergel J.M. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137. https://doi.org/10.1016/j.anai.2017.10.037.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Brown S.J., McLean W.H. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3):751–762. https://doi.org/10.1038/jid.2011.393.</mixed-citation><mixed-citation xml:lang="en">Brown S.J., McLean W.H. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3):751–762. https://doi.org/10.1038/jid.2011.393.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Матушевская Е.В., Свирщевская Е.В. Технологии микронизации лекарственных препаратов: новые возможности топических глюкокортикостероидов в дерматологии. Клиническая дерматология и венерология. 2017;(1):43–48. https://doi.org/10.17116/klinderma201716143-48.</mixed-citation><mixed-citation xml:lang="en">Matushevskaia E.V., Svirshchevskaia E.V. Drug micronization technique: new possibilities of topical corticosteroids in dermatology. Klinicheskaya Dermatologiya i Venerologiya. 2017;(1):43–48. (In Russ.) https://doi.org/10.17116/klinderma201716143-48.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Dabade T.S., Davis D.M., Wetter D.A., Hand J.L., McEvoy M.T., Pittelkow M.R. et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012;67(1):100–106. https://doi.org/10.1016/j.jaad.2011.06.025.</mixed-citation><mixed-citation xml:lang="en">Dabade T.S., Davis D.M., Wetter D.A., Hand J.L., McEvoy M.T., Pittelkow M.R. et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012;67(1):100–106. https://doi.org/10.1016/j.jaad.2011.06.025.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointmentin adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol. 2011;164(2):387–395. https://doi.org/10.1111/j.1365-2133.2010.10141.x.</mixed-citation><mixed-citation xml:lang="en">Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointmentin adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol. 2011;164(2):387–395. https://doi.org/10.1111/j.1365-2133.2010.10141.x.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Самцов А.В., Сухарев А.В., Патрушев А.В. Лечение атопического дерматита: преимущества такролимуса перед топическими кортикостероидами. Эффективная фармакотерапия. 2014;(2):4–10. Режим доступа: https://umedp.ru/articles/lechenie_atopicheskogo_dermatita_preimushchestva_takrolimusa_pered_topicheskimi_glyukokortikosteroid.html.</mixed-citation><mixed-citation xml:lang="en">Samtsov A.V., Sukharev A.V., Patrushev A.V. Treatment of atopic dermatitis: advantages of tacrolimus over topical corticosteroids. Effective Pharmacotherapy. 2014;(2):4–10. (In Russ.) Available at: https://umedp.ru/articles/lechenie_atopicheskogo_dermatita_preimushchestva_takrolimusa_pered_topicheskimi_glyukokortikosteroid.html.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьева И.Г. Применение комфодерма К и такропика для лечения атопического дерматита у детей. Дерматология в России. 2017;(Прил. 1):7–8. Режим доступа: https://www.ismu.baikal.ru/src/portfolio/14689.pdf.</mixed-citation><mixed-citation xml:lang="en">Afanasyeva I.G. The use of comfoderm K and tacropic for the treatment of atopic dermatitis in children. Dermatology in Russia. 2017;(1 Suppl.):7–8. (In Russ.) Available at: https://www.ismu.baikal.ru/src/portfolio/14689.pdf.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
